Review
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Jun 26, 2021; 13(6): 485-502
Published online Jun 26, 2021. doi: 10.4252/wjsc.v13.i6.485
Genome engineering and disease modeling via programmable nucleases for insulin gene therapy: Promises of CRISPR/Cas9 technology
Yunus E Eksi, Ahter D Sanlioglu, Bahar Akkaya, Bilge Esin Ozturk, Salih Sanlioglu
Yunus E Eksi, Ahter D Sanlioglu, Bahar Akkaya, Salih Sanlioglu, Department of Gene and Cell Therapy, Akdeniz University Faculty of Medicine, Antalya 07058, Turkey
Bilge Esin Ozturk, Department of Ophthalmology, University of Pittsburgh, Pittsburgh, PA 15213, United States
Author contributions: Eksi YE drafted the manuscript and prepared the figures; Sanlioglu AD prepared and revised the manuscript; Akkaya B and Ozturk BE revised the manuscript; Sanlioglu S designed both the study and the figures.
Supported by the Akdeniz University Scientific Research Commission and the Scientific and Technological Research Council of Turkey, No. TUBITAK-215S820.
Conflict-of-interest statement: The authors declare no conflict of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Salih Sanlioglu, VMD, PhD, Chairman, Professor, Department of Gene and Cell Therapy, Akdeniz University Faculty of Medicine, Dumlupınar Boulevard, Campus, Antalya 07058, Turkey. ssanlioglu@icloud.com
Received: January 27, 2021
Peer-review started: January 27, 2021
First decision: February 28, 2021
Revised: April 2, 2021
Accepted: June 16, 2021
Article in press: June 16, 2021
Published online: June 26, 2021
Processing time: 149 Days and 22.8 Hours
Core Tip

Core Tip: In this review, CRISPR/Cas9 nuclease is deployed in the generation of cellular and animal models of diabetes, which are suitable for the testing of the treatment efficacy of novel insulin gene therapy approaches.